董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Carolina Abenante | 女 | Director | 54 | 未披露 | 未持股 | 2025-09-09 |
| Warren Hirsch | 男 | Director | 67 | 18.93万美元 | 未持股 | 2025-09-09 |
| Louis Gleckel | 男 | Director | 69 | 18.93万美元 | 未持股 | 2025-09-09 |
| Ted Karkus | 男 | Chairman of the Board and Chief Executive Officer | 65 | 212.32万美元 | 未持股 | 2025-09-09 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ted Karkus | 男 | Chairman of the Board and Chief Executive Officer | 65 | 212.32万美元 | 未持股 | 2025-09-09 |
董事简历
中英对照 | 中文 | 英文- Carolina Abenante
-
Carolina Abenante是NYIAX的创始人。她于2016年成为副主席，在此之前于2011年至2016年担任NYIAX的唯一董事。她于2012年6月至2018年4月担任Nyiax，Inc.总裁，后于2018年4月成为Nyiax，Inc.首席战略官兼总法律顾问。从2022年5月23日起，她成为Nyiax，Inc.的首席布道者和首席战略官，同时不再担任总法律顾问。自1999年以来，她一直在纽约市的技术和广告行业工作，1999年至2000年，她担任Juno在线服务公司的公司发展总监，主要负责公司发展、兼并和收购以及国内和国际战略伙伴关系。2001-2005年，她成为Reed Elsevier Ltd（Reed Business Information）的业务发展高级总监，并成为该公司数字广告技术和广告团队的一员。Reed Elsevier Ltd（Reed Business Information）在美国（在纽约证券交易所和伦敦证交所上市）致力于通过Reed Elsevier数字出版家族创建和发展企业对企业出版合作伙伴关系，并将Reed Business Publications推向国外市场。2005-2009年，Phorm Inc.（AIM：PHRM）业务发展、法律和政策副总裁/高级总监，在美国和外国司法管辖区（即英国、巴西、意大利、西班牙和中国）制定战略和法律框架，进军其品牌和产品的国际化，与英国电信等公司合作进行行为广告。后来，她在2009年至2015年期间担任战略和业务发展方面的顾问和法律顾问，为寻求开发和创建程序化广告平台、广告运营和合规、电子商务和隐私等新战略的美国和国际初创企业以及传统出版商服务。Abenante女士于1992年5月在Seton Hall大学获得管理学和金融学学士学位，1997年5月在纽约法学院获得法学博士学位，并于1998年12月在意大利米兰的Luigi Bocconi大学SDA Bocconi管理学院获得综合管理学工商管理硕士学位。她是一名执业律师和新泽西州律师协会的成员。她是新泽西律师协会（税务和媒体）的多个新泽西律师协会和委员会的成员，也是美国律师协会的成员。她是国际隐私专业人员协会的长期会员。自2018年以来，她一直是“全球区块链女性”的成员和董事会成员。她是一位关于广告、广告技术和合规以及区块链的全球演讲者。她曾多次在英国伦敦帝国理工学院、葡萄牙里斯本网络峰会、IAB区块链和其他论坛上就广告、作为广告合规技术的区块链以及AdTech与FinTech的交叉领域发表演讲。她是数字商会2018年9月发布的《智能合约及其法律影响白皮书》的广告和媒体顾问和专家之一。她是广告行业的一名专业专家，撰写有关期权与广告和受众未来、数据隐私和数据洁净室的文章。她曾多次作为TechUpForWomen的特邀发言人就广告、招聘、加密货币和区块链发表演讲。此外，她还是NYIAX/纳斯达克 AB美国专利“变式库存电子连续交易的系统和方法”（专利号10,607，291）的发明人之一。
Carolina Abenante,is a Founder of NYIAX. She became Vice Chairperson in 2016 and prior to the time the sole director NYIAX from 2011 to 2016. She was Nyiax, Inc. President from June 2012 to April 2018 and later became Nyiax, Inc. Chief Strategy Officer and General Counsel in April 2018. Starting from May 23, 2022, she became Nyiax, Inc. Chief Evangelist and Chief Strategy Officer, and at the same time ceased to be General Counsel. She has been in the New York City technology and advertising industry since 1999, when she was the Director of Corporate Development for Juno Online Services, Inc. 1999-2000, focusing on corporate development, mergers and acquisitions and domestic and international strategic partnerships. In 2001-2005, she became the Senior Director of Business Development and was part of the digital advertising tech and advertising team for Reed Elsevier Ltd (Reed Business Information), in the U.S. (NYSE and LSE listed) working with creating and developing partnership for business-to-business publishing through the Reed Elsevier family of digital publication and bringing Reed Business Publications to foreign markets. In 2005-2009 Vice President/Sr. Director of Business Development, Legal and Policy for Phorm Inc. (AIM: PHRM), developing strategy, legal framework in US and foreign jurisdictions namely the United Kingdom, Brazil, Italy, Spain, and China inroads into internationalization of its brand and products for behavioral advertising collaborating with companies; such as, British Telecom. She later became a consultant and legal counsel in strategy and business development from 2009 to 2015 for US and International start-ups and traditional publishers seeking to develop new strategies for the development and creation of Programmatic advertising platforms, advertisement operation and compliance, e-commerce, and privacy. Ms. Abenante holds a Bachelor of Science degree in Management and Finance from Seton Hall University May 1992, a J.D. from New York Law School May 1997, and an M.B.A. in General Management from SDA Bocconi School of Management, Universita Luigi Bocconi in Milan, Italy December 1998. She is a practicing attorney and a member of the Bar of the State of New Jersey. She sits on various New Jersey Bar and committees of the New Jersey Bar Association (Tax and Media) and is a member of the American Bar Association. She is a long-standing member of the International Association of Privacy Professionals. She is a member and on the board of Global Women in Blockchain since 2018. She is a global speaker on advertising, advertising technology and compliance, as well as Blockchain. She has been a featured speaker at Imperial College London, England, Web Summit in Lisbon, Portugal, IAB Blockchain and other forums multiple times in the area of advertising, blockchain as a technology for compliance in advertising, and the intersection of AdTech to FinTech. She was one of the consultants and experts for advertising and media for the Digital Chamber of Commerce's White Paper on Smart Contracts and its legal implications published in September 2018. She is a featured advertising industry professional with articles on options intersection with advertising and audience futures, data privacy and data clean rooms. She has spoken multiple times as a featured speaker for TechUpForWomen on advertising, hiring, crypto currency and blockchain. Additionally, she is one of the inventors of the NYIAX/Nasdaq AB US patent on "Systems and Methods for Electronic Continuous Trading of Variant Inventories" (Patent No. 10,607,291). - Carolina Abenante是NYIAX的创始人。她于2016年成为副主席，在此之前于2011年至2016年担任NYIAX的唯一董事。她于2012年6月至2018年4月担任Nyiax，Inc.总裁，后于2018年4月成为Nyiax，Inc.首席战略官兼总法律顾问。从2022年5月23日起，她成为Nyiax，Inc.的首席布道者和首席战略官，同时不再担任总法律顾问。自1999年以来，她一直在纽约市的技术和广告行业工作，1999年至2000年，她担任Juno在线服务公司的公司发展总监，主要负责公司发展、兼并和收购以及国内和国际战略伙伴关系。2001-2005年，她成为Reed Elsevier Ltd（Reed Business Information）的业务发展高级总监，并成为该公司数字广告技术和广告团队的一员。Reed Elsevier Ltd（Reed Business Information）在美国（在纽约证券交易所和伦敦证交所上市）致力于通过Reed Elsevier数字出版家族创建和发展企业对企业出版合作伙伴关系，并将Reed Business Publications推向国外市场。2005-2009年，Phorm Inc.（AIM：PHRM）业务发展、法律和政策副总裁/高级总监，在美国和外国司法管辖区（即英国、巴西、意大利、西班牙和中国）制定战略和法律框架，进军其品牌和产品的国际化，与英国电信等公司合作进行行为广告。后来，她在2009年至2015年期间担任战略和业务发展方面的顾问和法律顾问，为寻求开发和创建程序化广告平台、广告运营和合规、电子商务和隐私等新战略的美国和国际初创企业以及传统出版商服务。Abenante女士于1992年5月在Seton Hall大学获得管理学和金融学学士学位，1997年5月在纽约法学院获得法学博士学位，并于1998年12月在意大利米兰的Luigi Bocconi大学SDA Bocconi管理学院获得综合管理学工商管理硕士学位。她是一名执业律师和新泽西州律师协会的成员。她是新泽西律师协会（税务和媒体）的多个新泽西律师协会和委员会的成员，也是美国律师协会的成员。她是国际隐私专业人员协会的长期会员。自2018年以来，她一直是“全球区块链女性”的成员和董事会成员。她是一位关于广告、广告技术和合规以及区块链的全球演讲者。她曾多次在英国伦敦帝国理工学院、葡萄牙里斯本网络峰会、IAB区块链和其他论坛上就广告、作为广告合规技术的区块链以及AdTech与FinTech的交叉领域发表演讲。她是数字商会2018年9月发布的《智能合约及其法律影响白皮书》的广告和媒体顾问和专家之一。她是广告行业的一名专业专家，撰写有关期权与广告和受众未来、数据隐私和数据洁净室的文章。她曾多次作为TechUpForWomen的特邀发言人就广告、招聘、加密货币和区块链发表演讲。此外，她还是NYIAX/纳斯达克 AB美国专利“变式库存电子连续交易的系统和方法”（专利号10,607，291）的发明人之一。
- Carolina Abenante,is a Founder of NYIAX. She became Vice Chairperson in 2016 and prior to the time the sole director NYIAX from 2011 to 2016. She was Nyiax, Inc. President from June 2012 to April 2018 and later became Nyiax, Inc. Chief Strategy Officer and General Counsel in April 2018. Starting from May 23, 2022, she became Nyiax, Inc. Chief Evangelist and Chief Strategy Officer, and at the same time ceased to be General Counsel. She has been in the New York City technology and advertising industry since 1999, when she was the Director of Corporate Development for Juno Online Services, Inc. 1999-2000, focusing on corporate development, mergers and acquisitions and domestic and international strategic partnerships. In 2001-2005, she became the Senior Director of Business Development and was part of the digital advertising tech and advertising team for Reed Elsevier Ltd (Reed Business Information), in the U.S. (NYSE and LSE listed) working with creating and developing partnership for business-to-business publishing through the Reed Elsevier family of digital publication and bringing Reed Business Publications to foreign markets. In 2005-2009 Vice President/Sr. Director of Business Development, Legal and Policy for Phorm Inc. (AIM: PHRM), developing strategy, legal framework in US and foreign jurisdictions namely the United Kingdom, Brazil, Italy, Spain, and China inroads into internationalization of its brand and products for behavioral advertising collaborating with companies; such as, British Telecom. She later became a consultant and legal counsel in strategy and business development from 2009 to 2015 for US and International start-ups and traditional publishers seeking to develop new strategies for the development and creation of Programmatic advertising platforms, advertisement operation and compliance, e-commerce, and privacy. Ms. Abenante holds a Bachelor of Science degree in Management and Finance from Seton Hall University May 1992, a J.D. from New York Law School May 1997, and an M.B.A. in General Management from SDA Bocconi School of Management, Universita Luigi Bocconi in Milan, Italy December 1998. She is a practicing attorney and a member of the Bar of the State of New Jersey. She sits on various New Jersey Bar and committees of the New Jersey Bar Association (Tax and Media) and is a member of the American Bar Association. She is a long-standing member of the International Association of Privacy Professionals. She is a member and on the board of Global Women in Blockchain since 2018. She is a global speaker on advertising, advertising technology and compliance, as well as Blockchain. She has been a featured speaker at Imperial College London, England, Web Summit in Lisbon, Portugal, IAB Blockchain and other forums multiple times in the area of advertising, blockchain as a technology for compliance in advertising, and the intersection of AdTech to FinTech. She was one of the consultants and experts for advertising and media for the Digital Chamber of Commerce's White Paper on Smart Contracts and its legal implications published in September 2018. She is a featured advertising industry professional with articles on options intersection with advertising and audience futures, data privacy and data clean rooms. She has spoken multiple times as a featured speaker for TechUpForWomen on advertising, hiring, crypto currency and blockchain. Additionally, she is one of the inventors of the NYIAX/Nasdaq AB US patent on "Systems and Methods for Electronic Continuous Trading of Variant Inventories" (Patent No. 10,607,291).
- Warren Hirsch
-
Warren Hirsch自2019年起一直是ProPhase Labs, Inc.董事会成员，目前担任薪酬委员会、提名和公司治理委员会成员，以及审计委员会主席。Hirsch先生拥有超过35年的注册会计师经验。Hirsch先生拥有并经营Hirsch和Hirsch CPA PLLC，后者提供全方位的会计、税务和小型企业咨询服务。2000年至2019年5月，Hirsch先生担任国家金融咨询公司Royal Alliance的注册代表。Hirsch先生于1980年毕业于霍夫斯特拉大学，获得会计学学士学位。
Warren Hirsch,has been a member of Prophase Labs, Inc. Board since 2019 and currently serves as a member of the Compensation Committee, Nominating and Corporate Governance Committee, and as chairman of the Audit Committee. Mr. Hirsch has over 35 years of experience as a Certified Public Accountant. Mr. Hirsch owns and operates Hirsch and Hirsch CPA PLLC, which offers a full range of accounting, tax and small business consulting services. From 2000 to May 2019, Mr. Hirsch served as a registered representative of Royal Alliance, a national financial advisory firm. Mr. Hirsch graduated with a bachelor's degree in accounting from Hofstra University in 1980. - Warren Hirsch自2019年起一直是ProPhase Labs, Inc.董事会成员，目前担任薪酬委员会、提名和公司治理委员会成员，以及审计委员会主席。Hirsch先生拥有超过35年的注册会计师经验。Hirsch先生拥有并经营Hirsch和Hirsch CPA PLLC，后者提供全方位的会计、税务和小型企业咨询服务。2000年至2019年5月，Hirsch先生担任国家金融咨询公司Royal Alliance的注册代表。Hirsch先生于1980年毕业于霍夫斯特拉大学，获得会计学学士学位。
- Warren Hirsch,has been a member of Prophase Labs, Inc. Board since 2019 and currently serves as a member of the Compensation Committee, Nominating and Corporate Governance Committee, and as chairman of the Audit Committee. Mr. Hirsch has over 35 years of experience as a Certified Public Accountant. Mr. Hirsch owns and operates Hirsch and Hirsch CPA PLLC, which offers a full range of accounting, tax and small business consulting services. From 2000 to May 2019, Mr. Hirsch served as a registered representative of Royal Alliance, a national financial advisory firm. Mr. Hirsch graduated with a bachelor's degree in accounting from Hofstra University in 1980.
- Louis Gleckel
-
Louis Gleckel，一直是Prophase Labs， Inc.的成员。自2009年6月起担任董事会成员，目前担任审计委员会、薪酬委员会成员，以及提名和公司治理委员会主席。1997年，Gleckel博士共同创立了ProHealth Care Associates，这是一家在纽约长岛和布朗克斯设有办事处的综合性多专业医师团体。在ProHealth，他是心脏病学和内科的部门主管，专门从事预防心脏病学、代谢综合征和内科，特别强调患有糖尿病和心脏病并发症的高风险患者。他连续三年入选《纽约杂志》最佳医生名单，连续14年入选纽约大都会区最佳医生名单，并于2008年入选拿骚县最佳医生名单。十多年来，他一直是纽约喷气机队和纽约岛民队的队医，也是美国网球公开赛的网球运动员的队医。他还曾担任Invicta Corporation（一个开发阶段的公司，设计、制造和销售光致变色眼镜镜片）的董事会主席，大约四年，直到他于2005年2月辞职。
Louis Gleckel,has been a member of Prophase Labs, Inc. Board since June 2009 and currently serves as a member of the Audit Committee, Compensation Committee, and as chairman of the Nominating and Corporate Governance Committee. In 1997, Dr. Gleckel co-founded ProHealth Care Associates, a comprehensive state of the art multi-specialty physician group practice with offices in Long Island and Bronx, New York. At ProHealth, he is the Division Chief of Cardiology and Internal Medicine specializing in Preventative Cardiology, Metabolic Syndrome and Internal Medicine with particular emphasis on high-risk patients with complications from diabetes and heart disease. He was named to New York Magazine's Best Doctors list for three years, New York Metro Area Best Doctors list for 14 years and the 2008 Nassau County Best Doctors list. For over ten years Dr. Gleckel has been a team physician for the New York Jets and New York Islanders as well as for the tennis players at the US Open. Dr. Gleckel also served as Chairman of the Board of Invicta Corporation, a development stage company that designed, manufactured and marketed photochromic eyeglass lenses, for approximately four years until his resignation in February 2005. - Louis Gleckel，一直是Prophase Labs， Inc.的成员。自2009年6月起担任董事会成员，目前担任审计委员会、薪酬委员会成员，以及提名和公司治理委员会主席。1997年，Gleckel博士共同创立了ProHealth Care Associates，这是一家在纽约长岛和布朗克斯设有办事处的综合性多专业医师团体。在ProHealth，他是心脏病学和内科的部门主管，专门从事预防心脏病学、代谢综合征和内科，特别强调患有糖尿病和心脏病并发症的高风险患者。他连续三年入选《纽约杂志》最佳医生名单，连续14年入选纽约大都会区最佳医生名单，并于2008年入选拿骚县最佳医生名单。十多年来，他一直是纽约喷气机队和纽约岛民队的队医，也是美国网球公开赛的网球运动员的队医。他还曾担任Invicta Corporation（一个开发阶段的公司，设计、制造和销售光致变色眼镜镜片）的董事会主席，大约四年，直到他于2005年2月辞职。
- Louis Gleckel,has been a member of Prophase Labs, Inc. Board since June 2009 and currently serves as a member of the Audit Committee, Compensation Committee, and as chairman of the Nominating and Corporate Governance Committee. In 1997, Dr. Gleckel co-founded ProHealth Care Associates, a comprehensive state of the art multi-specialty physician group practice with offices in Long Island and Bronx, New York. At ProHealth, he is the Division Chief of Cardiology and Internal Medicine specializing in Preventative Cardiology, Metabolic Syndrome and Internal Medicine with particular emphasis on high-risk patients with complications from diabetes and heart disease. He was named to New York Magazine's Best Doctors list for three years, New York Metro Area Best Doctors list for 14 years and the 2008 Nassau County Best Doctors list. For over ten years Dr. Gleckel has been a team physician for the New York Jets and New York Islanders as well as for the tennis players at the US Open. Dr. Gleckel also served as Chairman of the Board of Invicta Corporation, a development stage company that designed, manufactured and marketed photochromic eyeglass lenses, for approximately four years until his resignation in February 2005.
- Ted Karkus
-
Ted Karkus，自2009年6月起，担任董事会主席和首席执行官。Karkus先生，担任Forrester金融公司（Forrester Financial, LLC）管理人员，Forrester金融公司是2001年由Karkus先生创立的管理咨询公司。Forrester金融公司（Forrester Financial LLC）为新兴企业提供广泛的服务，包括工作资金的组建和筹集，以及为研发运营，营销，金融策略提供协助管理。Karkus先生，协助ID Biomedical的转变，ID Biomedical是一个流感疫苗制造商，在2005年以14多亿美元被卖给葛兰素-史克（GlaxoSmithKline）。Karkus先生拥有证券和资本市场25年的经验，包括两年在Fahnestock & Co . Inc.——一家提供全面服务的经纪公司，他担任机构股票（Institutional Equities）的高级副总裁、董事；和四年在S.G. Warburg——一家投资银行，他担任机构股票的销售员，开发了机构投资者的大型网络。1984年，Karkus先生毕业于哥伦比亚大学商学院（Columbia University Graduate School of Business），获得了MBA学位，他也在那里获得了Beta Gamma Sigma荣誉。1981年，他以优等成绩从塔夫斯大学（Tufts University）毕业。
Ted Karkus,has been the Chairman of the Board and the Chief Executive Officer of the Company since June 2009. Mr. Karkus was instrumental in assisting the turnaround of ID Biomedical, an influenza vaccine manufacturer, which in 2005 was sold to GlaxoSmithKline plc for over $1.4 billion. Mr. Karkus has twenty-five years of experience in securities and capital markets including two years with Fahnestock & Co. Inc., a full-service brokerage firm, where he was Senior Vice President, Director of Institutional Equities, and four years at S.G. Warburg, an investment bank, where he was an institutional equity salesman and developed a large network of institutional investors. Mr. Karkus graduated with an MBA from Columbia University Graduate School of Business in 1984 where he received Beta Gamma Sigma honors. He graduated Magna Cum Laude from Tufts University in 1981. - Ted Karkus，自2009年6月起，担任董事会主席和首席执行官。Karkus先生，担任Forrester金融公司（Forrester Financial, LLC）管理人员，Forrester金融公司是2001年由Karkus先生创立的管理咨询公司。Forrester金融公司（Forrester Financial LLC）为新兴企业提供广泛的服务，包括工作资金的组建和筹集，以及为研发运营，营销，金融策略提供协助管理。Karkus先生，协助ID Biomedical的转变，ID Biomedical是一个流感疫苗制造商，在2005年以14多亿美元被卖给葛兰素-史克（GlaxoSmithKline）。Karkus先生拥有证券和资本市场25年的经验，包括两年在Fahnestock & Co . Inc.——一家提供全面服务的经纪公司，他担任机构股票（Institutional Equities）的高级副总裁、董事；和四年在S.G. Warburg——一家投资银行，他担任机构股票的销售员，开发了机构投资者的大型网络。1984年，Karkus先生毕业于哥伦比亚大学商学院（Columbia University Graduate School of Business），获得了MBA学位，他也在那里获得了Beta Gamma Sigma荣誉。1981年，他以优等成绩从塔夫斯大学（Tufts University）毕业。
- Ted Karkus,has been the Chairman of the Board and the Chief Executive Officer of the Company since June 2009. Mr. Karkus was instrumental in assisting the turnaround of ID Biomedical, an influenza vaccine manufacturer, which in 2005 was sold to GlaxoSmithKline plc for over $1.4 billion. Mr. Karkus has twenty-five years of experience in securities and capital markets including two years with Fahnestock & Co. Inc., a full-service brokerage firm, where he was Senior Vice President, Director of Institutional Equities, and four years at S.G. Warburg, an investment bank, where he was an institutional equity salesman and developed a large network of institutional investors. Mr. Karkus graduated with an MBA from Columbia University Graduate School of Business in 1984 where he received Beta Gamma Sigma honors. He graduated Magna Cum Laude from Tufts University in 1981.
高管简历
中英对照 | 中文 | 英文- Ted Karkus
Ted Karkus，自2009年6月起，担任董事会主席和首席执行官。Karkus先生，担任Forrester金融公司（Forrester Financial, LLC）管理人员，Forrester金融公司是2001年由Karkus先生创立的管理咨询公司。Forrester金融公司（Forrester Financial LLC）为新兴企业提供广泛的服务，包括工作资金的组建和筹集，以及为研发运营，营销，金融策略提供协助管理。Karkus先生，协助ID Biomedical的转变，ID Biomedical是一个流感疫苗制造商，在2005年以14多亿美元被卖给葛兰素-史克（GlaxoSmithKline）。Karkus先生拥有证券和资本市场25年的经验，包括两年在Fahnestock & Co . Inc.——一家提供全面服务的经纪公司，他担任机构股票（Institutional Equities）的高级副总裁、董事；和四年在S.G. Warburg——一家投资银行，他担任机构股票的销售员，开发了机构投资者的大型网络。1984年，Karkus先生毕业于哥伦比亚大学商学院（Columbia University Graduate School of Business），获得了MBA学位，他也在那里获得了Beta Gamma Sigma荣誉。1981年，他以优等成绩从塔夫斯大学（Tufts University）毕业。
Ted Karkus,has been the Chairman of the Board and the Chief Executive Officer of the Company since June 2009. Mr. Karkus was instrumental in assisting the turnaround of ID Biomedical, an influenza vaccine manufacturer, which in 2005 was sold to GlaxoSmithKline plc for over $1.4 billion. Mr. Karkus has twenty-five years of experience in securities and capital markets including two years with Fahnestock & Co. Inc., a full-service brokerage firm, where he was Senior Vice President, Director of Institutional Equities, and four years at S.G. Warburg, an investment bank, where he was an institutional equity salesman and developed a large network of institutional investors. Mr. Karkus graduated with an MBA from Columbia University Graduate School of Business in 1984 where he received Beta Gamma Sigma honors. He graduated Magna Cum Laude from Tufts University in 1981.- Ted Karkus，自2009年6月起，担任董事会主席和首席执行官。Karkus先生，担任Forrester金融公司（Forrester Financial, LLC）管理人员，Forrester金融公司是2001年由Karkus先生创立的管理咨询公司。Forrester金融公司（Forrester Financial LLC）为新兴企业提供广泛的服务，包括工作资金的组建和筹集，以及为研发运营，营销，金融策略提供协助管理。Karkus先生，协助ID Biomedical的转变，ID Biomedical是一个流感疫苗制造商，在2005年以14多亿美元被卖给葛兰素-史克（GlaxoSmithKline）。Karkus先生拥有证券和资本市场25年的经验，包括两年在Fahnestock & Co . Inc.——一家提供全面服务的经纪公司，他担任机构股票（Institutional Equities）的高级副总裁、董事；和四年在S.G. Warburg——一家投资银行，他担任机构股票的销售员，开发了机构投资者的大型网络。1984年，Karkus先生毕业于哥伦比亚大学商学院（Columbia University Graduate School of Business），获得了MBA学位，他也在那里获得了Beta Gamma Sigma荣誉。1981年，他以优等成绩从塔夫斯大学（Tufts University）毕业。
- Ted Karkus,has been the Chairman of the Board and the Chief Executive Officer of the Company since June 2009. Mr. Karkus was instrumental in assisting the turnaround of ID Biomedical, an influenza vaccine manufacturer, which in 2005 was sold to GlaxoSmithKline plc for over $1.4 billion. Mr. Karkus has twenty-five years of experience in securities and capital markets including two years with Fahnestock & Co. Inc., a full-service brokerage firm, where he was Senior Vice President, Director of Institutional Equities, and four years at S.G. Warburg, an investment bank, where he was an institutional equity salesman and developed a large network of institutional investors. Mr. Karkus graduated with an MBA from Columbia University Graduate School of Business in 1984 where he received Beta Gamma Sigma honors. He graduated Magna Cum Laude from Tufts University in 1981.